213 related articles for article (PubMed ID: 14677527)
1. [Clinical study of the month. The CHARM study].
Kulbertus H
Rev Med Liege; 2003 Oct; 58(10):646-52. PubMed ID: 14677527
[TBL] [Abstract][Full Text] [Related]
2. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
3. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
[TBL] [Abstract][Full Text] [Related]
4. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Granger CB; McMurray JJ; Yusuf S; Held P; Michelson EL; Olofsson B; Ostergren J; Pfeffer MA; Swedberg K;
Lancet; 2003 Sep; 362(9386):772-6. PubMed ID: 13678870
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
Ostergren JB
J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
[TBL] [Abstract][Full Text] [Related]
6. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
Yusuf S; Pfeffer MA; Swedberg K; Granger CB; Held P; McMurray JJ; Michelson EL; Olofsson B; Ostergren J;
Lancet; 2003 Sep; 362(9386):777-81. PubMed ID: 13678871
[TBL] [Abstract][Full Text] [Related]
7. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.
Pfeffer MA; Swedberg K; Granger CB; Held P; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Yusuf S; Pocock S;
Lancet; 2003 Sep; 362(9386):759-66. PubMed ID: 13678868
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin inhibition in heart failure.
McMurray JJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S17-22. PubMed ID: 15526237
[TBL] [Abstract][Full Text] [Related]
9. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
Solomon SD; Wang D; Finn P; Skali H; Zornoff L; McMurray JJ; Swedberg K; Yusuf S; Granger CB; Michelson EL; Pocock S; Pfeffer MA
Circulation; 2004 Oct; 110(15):2180-3. PubMed ID: 15466644
[TBL] [Abstract][Full Text] [Related]
10. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
Demers C; McMurray JJ; Swedberg K; Pfeffer MA; Granger CB; Olofsson B; McKelvie RS; Ostergren J; Michelson EL; Johansson PA; Wang D; Yusuf S;
JAMA; 2005 Oct; 294(14):1794-8. PubMed ID: 16219883
[TBL] [Abstract][Full Text] [Related]
11. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
[TBL] [Abstract][Full Text] [Related]
12. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Yusuf S
Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644318
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
Hawkins NM; Wang D; McMurray JJ; Pfeffer MA; Swedberg K; Granger CB; Yusuf S; Pocock SJ; Ostergren J; Michelson EL; Dunn FG;
Heart; 2007 Jan; 93(1):59-64. PubMed ID: 16952975
[TBL] [Abstract][Full Text] [Related]
14. Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.
Swedberg K; Pfeffer M; Granger C; Held P; McMurray J; Ohlin G; Olofsson B; Ostergren J; Yusuf S
J Card Fail; 1999 Sep; 5(3):276-82. PubMed ID: 10496201
[TBL] [Abstract][Full Text] [Related]
15. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
McMurray JJ; Andersson FL; Stewart S; Svensson K; Solal AC; Dietz R; Vanhaecke J; van Veldhuisen DJ; Ostergren J; Granger CB; Yusuf S; Pfeffer MA; Swedberg K
Eur Heart J; 2006 Jun; 27(12):1447-58. PubMed ID: 16754631
[TBL] [Abstract][Full Text] [Related]
16. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
Cohen-Solal A; McMurray JJ; Swedberg K; Pfeffer MA; Puu M; Solomon SD; Michelson EL; Yusuf S; Granger CB;
Eur Heart J; 2008 Dec; 29(24):3022-8. PubMed ID: 18987098
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
Hawkins NM; Wang D; McMurray JJ; Pfeffer MA; Swedberg K; Granger CB; Yusuf S; Pocock SJ; Ostergren J; Michelson EL; Dunn FG;
Eur J Heart Fail; 2007 May; 9(5):510-7. PubMed ID: 17317308
[TBL] [Abstract][Full Text] [Related]
18. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
Pocock S; Wang D; Wilhelmsen L; Hennekens CH
Am Heart J; 2005 May; 149(5):939-43. PubMed ID: 15894981
[TBL] [Abstract][Full Text] [Related]
19. ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials.
Sica DA
Congest Heart Fail; 2004; 10(3):160-4. PubMed ID: 15184734
[TBL] [Abstract][Full Text] [Related]
20. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Olofsson B; Puu M; Yusuf S;
Am Heart J; 2006 Jul; 152(1):86-92. PubMed ID: 16838426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
